Establishing a link between oncogenes and tumor angiogenesis

Molecular Medicine

Volumn 4, Issue 5, 1998, Pages 286-295

  Kerbel, Robert S ^a   Viloria Petit, Alicia ^b   Okada, Futoshi ^b   Rak, Janusz ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CELL PROLIFERATION; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSFECTION; NEOVASCULARIZATION (PATHOLOGY); NORTHERN BLOTTING; ONCOGENE; ONCOGENE H RAS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0031858958     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401737     Document Type: Review

References (71)

1. Hanahan D, Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
2. Fearon ER, Vogelstein B. (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
3. Folkman J. (1971) Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285: 1182-1186.
4. Folkman J. (1972) Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg. 175: 409-416.
5. Folkman J. (1990) What is the evidence that tumors are angiogenesis-dependent? J. Natl. Cancer Inst. 82: 4-6.
6. Bouck N, Stellmach V, Hsu SC. (1996) How tumors become angiogenic. Adv. Cancer Res. 69: 135-174.
7. Kerbel RS. (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13: 31-36.
8. Boehm T, Folkman J, Browder T, et al. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407.
9. Kerbel RS. (1997) A cancer therapy resistant to resistance. Nature 390: 335-336.
10. Folkman J, D'Amore PA. (1996) Blood vessel formation: What is its molecular basis? Cell 87: 1153-1155.
11. Terman BI, Dougher-Vermazen M. (1996) Biological properties of VEGF/VPF receptors. Cancer Metastasis Rev. 15: 159-163.
12. Thomas KA. (1996) Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271: 603-606.
13. Stromblad S, Cheresh DA. (1998) Cell adhesion and angiogenesis. Trends Cell Biol. 6: 462-468.
14. Brooks PC. (1996) Cell adhesion molecules in angiogenesis. Cancer Metastasis Rev. 15: 187-194.
15. Bischoff J. (1995) Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol. 5: 69-74.
16. Folkman J. (1995) Angiogenesis inhibitors generated by tumors. Mol. Med. 1: 120-122.
17. Baird A, Klagsbrun M. (1991) The fibroblast growth factor family. Cancer Cells 3: 239-243.
18. Rak J, Kerbel RS. (1997) bFGF and tumor angiogenesis - back in the limelight? Nat. Med. 3: 1083-1084.
19. Dameron KM, Volpert OV, Tainsky MA, et al. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584.
20. Bouck N. (1990) Tumor angiogenesis: The role of oncogenes and tumor suppressor genes. Cancer Cells 2: 179-185.
21. Cleveland DW, Lopata MA, MacDonald RJ, et al. (1980) Number and evolutionary conservation of alpha- and beta-tubulin and cytoplasmic beta-and gamma-actin genes using specific cloned cDNA probes. Cell 20: 95-105.
22. Roberts AB, Sporn MB, Assoian RK, et al. (1986) Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. U.S.A. 83: 4167-4171.
23. Iberg N, Rogelj S, Fanning P, et al. (1989) Purification of 18- and 22-kDa forms of basic fibroblast growth factor from rat cells transformed by the ras oncogene. J. Biol. Chem. 264: 19951-19955.
24. Tannock I. (1978) Cell kinetics and chemotherapy: A critical review. Cancer Treat. Reports 62: 1117-1133.
25. Olive PL, Durand RE. (1994) Drug and radiation resistance in spheroids: Cell contact and kinetics. Cancer Metastasis Rev. 13: 121-138.
26. Berges RR, Vukanovic J, Epstein J, et al. (1995) Implication of cell kinetic changes during the progression of human prostatic carcinoma. Clin. Cancer Res. 1: 473-480.
27. Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nat. Med. 2: 1204-1210.
28. Kohl NE, Mosser SD, deSolms SJ, et al. (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934-1942.
29. James GL, Golstein JL, Brown MS, et al. (1993) Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 260: 1937-1942.
30. Mendelsohn J, Fan Z. (1997) Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst. 89: 341-343.
31. Fendly BM, Winget M, Hudziak RM, et al. (1990) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50: 1550-1558.
32. Goldstein NI, Prewett M, Zuklys K, et al. (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1: 1311-1318.
33. Kohl NE, Omer CA, Conner MW, et al. (1995) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1: 792-797.
34. Ohnishi Y, Nakamura H, Yoshimura M, et al. (1995) Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antibody. Br. J. Cancer 71: 969-973.
35. Rak J, Mitsuhashi Y, Erdos V, et al. (1995) Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: Suppression by expression of a mutant c-H-ras oncogene. J. Cell Biol. 131: 1587-1598.
36. Lebowitz P, Sakamuro D, Prendergast GC. (1997) Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res. 57: 708-713.
37. Barrington RE, Subler MA, Rands E, et al. (1998) A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol. 18: 85-92.
38. Rak J, Mitsuhashi Y, Bayko L, et al. (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55: 4575-4580.
39. Folkman J. (1995) Clinical applications of research on angiogenesis. New Engl. J. Med. 333: 1757-1763.
40. O'Reilly MS, Holmgren L, Chen C, et al. (1996) Angiostatin induces canal sustains dormancy of human tumors in mice. Nat. Med. 2: 689-692.
41. Cheng SY, Huang HJ, Nagane M, et al. (1996) Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U.S.A. 93: 8502-8507.
42. Benjamin LE, Keshet E. (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. U.S.A. 94: 8761-8766.
43. Alon T, Hemo I, Itin A, et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1: 1024-1028.
44. Okada F, Rak J, St. Croix B, et al. (1998) Impact of oncogenes on tumor angiogenesis: mutant K-ras up-regulation of VEGF/VPF is necessary but not sufficient tor tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 35: 3609-3614.
45. Grugel S, Finkenzeller G, Weindel K, et al. (1995) Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270: 25915-25919.
46. Saez, E, Rutberg SE, Mueller E, et al. (1995) c-fos is required for malignant progression for skin tumors. Cell 82: 721-732.
47. Mazure NM, Chen EY, Yeh P, et al. (1996) Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56: 3436-3440.
48. Larcher F, Robles AI, Duran H, et al. (1996) Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res. 56: 5391-5396.
49. Volpert OV, Dameron KM, Bouck N. (1997) Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14: 1495-1502.
50. Mazure NM, Chen EY, Laderoute KR, et al. (1997) Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322-3331.
51. Lingen MW, DiPietro LA, Solt DB, et al. (1997) The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation. Carcinogenesis 18: 329-338.
52. Arbiser JL, Moses MA, Fernandez CA, et al. (1997) Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. U.S.A. 94: 861-866.
53. Enholm B, Paavonen K, Ristimaki A, et al. (1997) Comparison of VEGF, VEGF-B, VEGF-C and Ang-I mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14: 2475-2483.
54. White FC, Benehacene A, Scheele JS, et al. (1997) VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation - evidence for divergent stabilization pathways. Growth Factors 14: 199-212.
55. Shirasawa S, Furuse M, Yokoyama N, et al. (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88.
56. Viloria-Petit AM, Rak J, Hung M-C, et al. (1997) Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151: 1523-1530.
57. Goldman CK, Kim J, Wong WL, et al. (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 4: 121-133.
58. Goad DL, Rubin J, Wang H, et al. (1996) Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137: 2262-2268.
59. Kevil CG, De Benedetti A, Payne DK, et al. (1996) Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis. Int. J. Cancer 65: 785-790.
60. Zabrenetzky V, Harris CC, Steeg PS, et al. (1994) Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 59: 191-195.
61. Sheibani N, Frazier WA. (1996) Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. Cancer Lett. 107: 45-52.
62. Siemeister G, Weindel K, Mohrs K, et al. (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56: 2299-2301.
63. Mukhopadhyay D, Knebelmann B, Cohen HT, et al. (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17: 5629-5639.
64. Shweiki D, Itin A, Soffer D, et al. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initated angiogenesis. Nature 359: 843-845.
65. Shweiki D, Neeman M, Itin A, et al. (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 92: 768-772.
66. Ikeda E, Achen MG, Breier G, et al. (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem. 270: 19761-19766.
67. Stein I, Neeman M, Shweiki D, et al. (1995) Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol. Cell. Biol. 15: 5363-5368.
68. D'Amore PA, Shima DT. (1996) Tumor angiogenesis: a physiological process or genetically determined? Cancer Metastasis Rev. 15: 205-212.
69. Thompson TC, Southgate J, Kitchener G, et al. (1989) Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56: 917-930.
70. Fan Z, Mendelsohn J. (1998) Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol. 10: 67-73.
71. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gerhengorn MC, Mesri EA. (1998) G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391: 86-89.